BC
MCID: BRS047
MIFTS: 100

Breast Cancer (BC)

Categories: Genetic diseases, Rare diseases, Cancer diseases, Reproductive diseases

Aliases & Classifications for Breast Cancer

MalaCards integrated aliases for Breast Cancer:

Name: Breast Cancer 57 12 76 25 75 37 13 55 6 43 3 15 63
Breast Carcinoma 12 25 75 29 55 6 15 73
Breast Cancer, Familial 57 76 53 25 73
Breast Cancer, Lobular 57 38 29 6
Male Breast Cancer 12 53 43 15
Breast Cancer, Susceptibility to 57 29 6
Malignant Neoplasm of Breast 12 25 73
Breast Cancer, Early-Onset 57 29 6
Carcinoma of Male Breast 29 6 73
Breast Cancer, Protection Against 57 6
Malignant Neoplasm of Male Breast 12 73
Invasive Ductal Breast Carcinoma 55 73
Breast Cancer, Invasive Ductal 57 38
Hereditary Breast Carcinoma 53 59
Familial Breast Carcinoma 53 59
Familial Cancer of Breast 29 6
Breast Lobular Carcinoma 12 15
Hereditary Breast Cancer 53 59
Breast Cancer, Somatic 57 6
Familial Breast Cancer 53 59
Neoplasm of the Breast 29 6
Breast Cancer, Male 57 53
Mammary Carcinoma 12 75
Mammary Cancer 12 25
Mammary Tumor 12 55
Breast Cancer, Male, Susceptibility to 57
Primary Malignant Neoplasm of Breast 73
Malignant Tumor of the Breast 12
Breast Cancer Susceptibility 57
Breast Cancer, Familial Male 29
Breast Cancer Familial Male 75
Malignant Tumor of Breast 25
Cancer, Breast, Familial 40
Animal Mammary Neoplasms 73
Neoplasm of Male Breast 12
Heritable Breast Cancer 53
Cancer, Breast, Lobular 40
Breast Cancer Familial 75
Breast Neoplasms, Male 44
Primary Breast Cancer 12
Male Breast Carcinoma 53
Genetic Breast Cancer 53
Breast Male Carcinoma 55
Breast Cancer in Men 53
Carcinoma of Breast 12
Mammary Neoplasms 73
Mammary Neoplasm 12
Cancer of Breast 25
Breast Neoplasms 44
Cancer, Breast 40
Breast Tumor 12
Bc 75

Characteristics:

OMIM:

57
Inheritance:
autosomal dominant

Miscellaneous:
genetic heterogeneity


HPO:

32
breast cancer:
Inheritance autosomal dominant inheritance heterogeneous


Classifications:



Summaries for Breast Cancer

NIH Rare Diseases : 53 Familial breast cancer is a cluster of breast cancer within a family. Most cases of breast cancer occur sporadically in people with little to no family history of the condition. Approximately 5-10% of breast cancer is considered "hereditary" and is thought to be caused by an inherited predisposition to breast cancer that is passed down through a family in an autosomal dominant manner. In some of these families, the underlying genetic cause is not known; however, many of these cases are caused by changes (mutations) in the BRCA1, BRCA2, PTEN, TP53, CDH1, or STK11 genes (which are each associated with a unique hereditary cancer syndrome). Additional genes, such as CHEK2, BRIP1, RAD51, and ATM, are associated with breast and/or gynecologic cancers in some cases. About 15-20% of women diagnosed with breast cancer have a significant family history of breast cancer (two or more first-degree or second-degree relatives with breast cancer) but have no identifiable mutation in a gene known to cause a hereditary predisposition to breast cancer. These clusters of breast cancer are likely due to a combination of gene(s) and other shared factors such as environment and lifestyle.High-risk cancer screening and other preventative measures such as chemoprevention and/or prophylactic surgeries are typically recommended in women who have an increased risk for breast cancer based on their personal and/or family histories.

MalaCards based summary : Breast Cancer, also known as breast carcinoma, is related to sporadic breast cancer and bilateral breast cancer, and has symptoms including pelvic pain, lameness, animal and pain. An important gene associated with Breast Cancer is BRCA2 (BRCA2, DNA Repair Associated), and among its related pathways/superpathways are Breast cancer and MicroRNAs in cancer. The drugs Abraxane and Afinitor have been mentioned in the context of this disorder. Affiliated tissues include breast, bone and lymph node, and related phenotypes are breast carcinoma and Decreased viability

OMIM : 57 Breast cancer (referring to mammary carcinoma, not mammary sarcoma) is histopathologically and almost certainly etiologically and genetically heterogeneous. Important genetic factors have been indicated by familial occurrence and bilateral involvement. (114480)

UniProtKB/Swiss-Prot : 75 Breast cancer: A common malignancy originating from breast epithelial tissue. Breast neoplasms can be distinguished by their histologic pattern. Invasive ductal carcinoma is by far the most common type. Breast cancer is etiologically and genetically heterogeneous. Important genetic factors have been indicated by familial occurrence and bilateral involvement. Mutations at more than one locus can be involved in different families or even in the same case.

MedlinePlus : 43 Breast cancer affects one in eight women during their lives. No one knows why some women get breast cancer, but there are many risk factors. Risks that you cannot change include Age - the risk rises as you get older Genes - two genes, BRCA1 and BRCA2, greatly increase the risk. Women who have family members with breast or ovarian cancer may wish to be tested for the genes. Personal factors - beginning periods before age 12 or going through menopause after age 55 Other risks include obesity, using hormone replacement therapy (also called menopausal hormone therapy), taking birth control pills, drinking alcohol, not having children or having your first child after age 35, and having dense breasts. Symptoms of breast cancer may include a lump in the breast, a change in size or shape of the breast, and discharge from a nipple. Breast self-exams and mammography can help find breast cancer early, when it is most treatable. One possible treatment is surgery. It could be a lumpectomy or a mastectomy. Other treatments include radiation therapy, chemotherapy, hormone therapy, and targeted therapy. Targeted therapy uses substances that attack cancer cells without harming normal cells. Men can have breast cancer, too, but it is rare. NIH: National Cancer Institute

CDC : 3 Breast cancer is a group of diseases that affects breast tissue. Both women and men can get breast cancer, though it is much more common in women. Other than skin cancer, breast cancer is the most common cancer among women in the United States. Some women are at higher risk for breast cancer than others because of their personal or family medical history or because of certain changes in their genes.

Genetics Home Reference : 25 Breast cancer is a disease in which certain cells in the breast become abnormal and multiply uncontrollably to form a tumor. Although breast cancer is much more common in women, this form of cancer can also develop in men. In both women and men, the most common form of breast cancer begins in cells lining the milk ducts (ductal cancer). In women, cancer can also develop in the glands that produce milk (lobular cancer). Most men have little or no lobular tissue, so lobular cancer in men is very rare.

Disease Ontology : 12 A thoracic cancer that originates in the mammary gland.

Novus Biologicals : 56 Breast cancer is a malignant tumor that originates from breast tissue cells. Although most breast cancers initiate in the cells that line the breast ducts, some begin in the breast lobules and other tissues. As with all cancers, there is a genetic and environmental component of developing breast cancer. Women with defects in the BRCA1 and BRCA2 genes have up to an 80% chance of getting breast cancer. Research has also found that defects in the ErbB-2 gene lead to increased levels of the protein cyclin D1. Cyclin D1 then activates CDK4, which causes proliferation of cellular division. Blocking CDK4 activity may lead to effective breast cancer treatments.

PubMed Health : 63 About breast cancer: Being diagnosed with breast cancer often comes as a shock at first, and makes people feel very frightened and anxious. Having cancer can really turn your life upside down for a while. It helps to know that if you get breast cancer for the first time and it hasn’t spread far, there’s a good chance that treatment can lead to full recovery. There are also many support services that help people in everyday life, to return to work and cope emotionally with breast cancer.

Wikipedia : 76 Breast cancer is cancer that develops from breast tissue. Signs of breast cancer may include a lump in... more...

Related Diseases for Breast Cancer

Diseases in the Breast Cancer family:

Breast Benign Neoplasm Inflammatory Breast Carcinoma
Sporadic Breast Cancer Breast Carcinoma in Situ

Diseases related to Breast Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 814)
# Related Disease Score Top Affiliating Genes
1 sporadic breast cancer 37.4 ATM BARD1 BRCA1 BRCA2 CHEK2 ESR1
2 bilateral breast cancer 37.2 ATM BRCA1 BRCA2 CHEK2 ESR1 RAD51
3 female breast cancer 37.1 ATM BRCA1 BRCA2 ESR1 PALB2 PHB
4 estrogen-receptor positive breast cancer 36.4 AKT1 ESR1 PIK3CA TP53
5 ovarian cancer 36.2 AKT1 ATM BARD1 BRCA1 BRCA2 BRIP1
6 hereditary breast ovarian cancer syndrome 35.7 ATM BARD1 BRCA1 BRCA2 BRIP1 CHEK2
7 li-fraumeni syndrome 35.7 ATM BRCA1 BRCA2 CHEK2 TP53
8 adenocarcinoma 35.2 AKT1 CDH1 KRAS PIK3CA TP53
9 prostate cancer 35.1 AKT1 BRCA1 BRCA2 CASP8 CDH1 CHEK2
10 lung cancer 35.0 AKT1 ATM CASP8 CDH1 CHEK2 KRAS
11 colorectal cancer 34.9 AKT1 ATM BRCA1 BRCA2 CASP8 CDH1
12 ductal carcinoma in situ 34.5 AKT1 BRCA1 BRCA2 CDH1 ESR1 TP53
13 endometrial cancer 34.3 AKT1 BRCA1 BRCA2 CDH1 ESR1 KRAS
14 pancreatic cancer 34.0 AKT1 BRCA1 BRCA2 CDH1 KRAS PALB2
15 li-fraumeni syndrome 2 34.0 CHEK2 TP53
16 fanconi anemia, complementation group a 34.0 ATM BRCA1 BRCA2 BRIP1 PALB2 RAD51
17 ovarian cancer 1 33.6 AKT1 BRCA1 BRCA2 CDH1 KRAS PIK3CA
18 ataxia-telangiectasia 33.6 ATM BRCA1 CHEK2 TP53
19 wilms tumor 1 33.4 BRCA2 CHEK2 ESR1 KRAS TP53
20 esophageal cancer 33.4 AKT1 CDH1 CHEK2 KRAS PIK3CA RAD51
21 cowden disease 33.3 AKT1 BRCA1 BRCA2 PIK3CA
22 breast carcinoma in situ 33.2 BRCA1 BRCA2 CDH1 ESR1 TP53
23 squamous cell carcinoma 33.2 AKT1 CDH1 KRAS PIK3CA TP53
24 breast ductal carcinoma 33.2 BRCA1 CDH1 ESR1 TP53
25 lynch syndrome 33.1 BRCA1 BRCA2 KRAS TP53
26 lung cancer susceptibility 3 33.1 AKT1 CASP8 CDH1 KRAS PIK3CA TP53
27 breast reconstruction 33.1 BRCA1 BRCA2
28 thyroid cancer 33.1 AKT1 CDH1 KRAS PIK3CA TP53
29 mutagen sensitivity 33.0 BRCA1 BRCA2 TP53 XRCC3
30 in situ carcinoma 33.0 BRCA1 CDH1 ESR1 TP53
31 nijmegen breakage syndrome 33.0 ATM BRCA1 CHEK2 TP53
32 brain cancer 33.0 AKT1 BRCA2 CASP8 PIK3CA RAD51 TP53
33 adenoid cystic carcinoma 33.0 AKT1 CDH1 CHEK2 KRAS PIK3CA TP53
34 xeroderma pigmentosum, variant type 32.9 ATM RAD51 TP53 XRCC3
35 myeloma, multiple 32.9 AKT1 CASP8 KRAS TP53
36 cholangiocarcinoma 32.8 AKT1 CDH1 KRAS PIK3CA TP53
37 fallopian tube carcinoma 32.7 BRCA1 BRCA2 ESR1 TP53
38 endometrial adenocarcinoma 32.7 AKT1 ESR1 KRAS TP53
39 lymphoma, non-hodgkin, familial 32.5 ATM CASP8 PIK3CA TP53
40 medulloblastoma 32.5 AKT1 BRCA2 CASP8 PIK3CA TP53
41 lobular neoplasia 32.4 BRCA1 CDH1 ESR1
42 squamous cell carcinoma, head and neck 32.3 AKT1 CDH1 PIK3CA TP53
43 uterine carcinosarcoma 32.3 CDH1 PIK3CA TP53
44 skin squamous cell carcinoma 32.1 KRAS PIK3CA TP53
45 colon adenocarcinoma 31.3 CASP8 CDH1 KRAS
46 ovary epithelial cancer 12.8 AKT1 BRCA1 BRCA2 CDH1 ESR1 KRAS
47 female reproductive organ cancer 12.8 AKT1 BRCA1 BRCA2 CDH1 ESR1 KRAS
48 adamantinoma of long bones 12.8 BRCA1 BRCA2 CASP8 CDH1 ESR1 KRAS
49 breast adenocarcinoma 12.7 AKT1 CASP8 ESR1 KRAS PIK3CA RB1CC1
50 malignant ovarian surface epithelial-stromal neoplasm 12.7 AKT1 BRCA1 BRCA2 CDH1 KRAS PIK3CA

Graphical network of the top 20 diseases related to Breast Cancer:



Diseases related to Breast Cancer

Symptoms & Phenotypes for Breast Cancer

Symptoms via clinical synopsis from OMIM:

57
Neoplasia:
breast carcinoma


Clinical features from OMIM:

114480

Human phenotypes related to Breast Cancer:

32
# Description HPO Frequency HPO Source Accession
1 breast carcinoma 32 HP:0003002

UMLS symptoms related to Breast Cancer:


pelvic pain, lameness, animal, pain

GenomeRNAi Phenotypes related to Breast Cancer according to GeneCards Suite gene sharing:

26 (show all 39)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 10.95 KRAS PIK3CA
2 Decreased viability GR00106-A-0 10.95 KRAS
3 Decreased viability GR00221-A-1 10.95 AKT1 CDH1 ESR1 KRAS PIK3CA
4 Decreased viability GR00221-A-2 10.95 AKT1 BRCA1 ESR1 KRAS CHEK2 PIK3CA
5 Decreased viability GR00221-A-3 10.95 AKT1 ATM BRCA1 CHEK2
6 Decreased viability GR00221-A-4 10.95 AKT1 ATM ESR1 CHEK2 PIK3CA
7 Decreased viability GR00301-A 10.95 CDH1 BRCA1 KRAS
8 Decreased viability GR00342-S-2 10.95 CHEK2
9 Decreased viability GR00381-A-1 10.95 KRAS
10 Decreased viability GR00402-S-2 10.95 AKT1 ATM CDH1 CHEK2 BRCA1 KRAS
11 Decreased homologous recombination repair frequency GR00151-A-1 10.79 BARD1 BRCA1 RAD51
12 Decreased homologous recombination repair frequency GR00151-A-2 10.79 BRCA1 RAD51
13 Decreased homologous recombination repair frequency GR00236-A-1 10.79 BARD1 BRCA1 BRCA2 PALB2 RAD51 TSG101
14 Decreased homologous recombination repair frequency GR00236-A-2 10.79 BARD1 ATM BRCA1 BRCA2 PALB2 TSG101
15 Decreased homologous recombination repair frequency GR00236-A-3 10.79 BRCA1 BARD1 BRCA2 PALB2 RAD51
16 Decreased shRNA abundance (Z-score < -2) GR00366-A-117 10.46 KRAS
17 Decreased shRNA abundance (Z-score < -2) GR00366-A-119 10.46 TSG101
18 Decreased shRNA abundance (Z-score < -2) GR00366-A-139 10.46 BRCA1
19 Decreased shRNA abundance (Z-score < -2) GR00366-A-145 10.46 KRAS
20 Decreased shRNA abundance (Z-score < -2) GR00366-A-165 10.46 KRAS
21 Decreased shRNA abundance (Z-score < -2) GR00366-A-193 10.46 KRAS
22 Decreased shRNA abundance (Z-score < -2) GR00366-A-204 10.46 BRCA1
23 Decreased shRNA abundance (Z-score < -2) GR00366-A-211 10.46 BRCA1
24 Decreased shRNA abundance (Z-score < -2) GR00366-A-216 10.46 KRAS PIK3CA TSG101
25 Decreased shRNA abundance (Z-score < -2) GR00366-A-22 10.46 KRAS
26 Decreased shRNA abundance (Z-score < -2) GR00366-A-27 10.46 KRAS
27 Decreased shRNA abundance (Z-score < -2) GR00366-A-33 10.46 KRAS
28 Decreased shRNA abundance (Z-score < -2) GR00366-A-40 10.46 PHB
29 Decreased shRNA abundance (Z-score < -2) GR00366-A-53 10.46 BRCA1 KRAS PHB PIK3CA TSG101
30 Decreased shRNA abundance (Z-score < -2) GR00366-A-60 10.46 PIK3CA
31 Decreased shRNA abundance (Z-score < -2) GR00366-A-66 10.46 KRAS
32 Decreased shRNA abundance (Z-score < -2) GR00366-A-71 10.46 BRCA1
33 Decreased viability in esophageal squamous lineage GR00235-A 10.1 CDH1 CHEK2 BRCA2 BRCA1 KRAS ESR1
34 Decreased ionizing radiation sensitivity GR00232-A-1 10.03 AKT1 BARD1 ATM CDH1 BRCA1 BRCA2
35 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 10.02 BRCA1 ATM AKT1 BARD1 CASP8 BRCA2
36 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 10.02 BRCA1 ATM AKT1 BARD1 CASP8 BRCA2
37 Increased viability with MLN4924 (a NAE inhibitor) GR00250-A-3 9.93 BRCA1 ATM BARD1 CASP8 BRCA2 CHEK2
38 Decreased viability with cisplatin GR00101-A-4 9.65 BRCA1 BARD1 BRCA2 BRIP1 RAD51
39 Synthetic lethal with cisplatin GR00101-A-1 9.43 BRCA1 BARD1 BRCA2 BRIP1 RAD51 XRCC3

MGI Mouse Phenotypes related to Breast Cancer:

46 (show all 16)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.48 ATM BRCA2 AKT1 BARD1 BRCA1 TSG101
2 growth/size/body region MP:0005378 10.39 BRCA1 ATM BARD1 AKT1 TSG101 TP53
3 embryo MP:0005380 10.38 ATM BRCA2 AKT1 BARD1 BRCA1 TSG101
4 endocrine/exocrine gland MP:0005379 10.37 BRCA1 ATM AKT1 TSG101 TP53 CHEK2
5 homeostasis/metabolism MP:0005376 10.35 BRCA1 ATM AKT1 RB1CC1 TSG101 TP53
6 mortality/aging MP:0010768 10.32 BRCA1 ATM BRCA2 BARD1 AKT1 TSG101
7 cardiovascular system MP:0005385 10.3 AKT1 BRCA1 ATM TP53 RB1CC1 CDH1
8 integument MP:0010771 10.28 BRCA1 ATM BRCA2 AKT1 TSG101 RB1CC1
9 immune system MP:0005387 10.27 BRCA1 ATM AKT1 RB1CC1 XRCC3 TP53
10 hematopoietic system MP:0005397 10.24 AKT1 BRCA1 ATM TP53 RB1CC1 XRCC3
11 neoplasm MP:0002006 10.13 ATM BRCA2 AKT1 BARD1 BRCA1 TSG101
12 nervous system MP:0003631 9.97 BRCA1 ATM BARD1 AKT1 TP53 BRIP1
13 liver/biliary system MP:0005370 9.95 AKT1 TP53 RB1CC1 BRIP1 CASP8 KRAS
14 muscle MP:0005369 9.92 AKT1 BRCA1 TP53 RB1CC1 CASP8 KRAS
15 normal MP:0002873 9.65 AKT1 BRCA1 BARD1 TP53 RB1CC1 TSG101
16 reproductive system MP:0005389 9.36 BRCA1 ATM AKT1 TP53 BRIP1 BRCA2

Drugs & Therapeutics for Breast Cancer

PubMedHealth treatment related to Breast Cancer: 63

The treatment options always depend on the type and size of the tumor, where it has spread to (if it has spread), the patient’s general health, as well as their personal preferences. Breast cancer can be treated with surgery, radiation and medication. Different treatment approaches are often combined.The standard treatment is to try to surgically remove as much of the tumor as possible. Neighboring lymph nodes are sometimes also removed. If the tumor is small, women are often faced with a decision: Should they keep the breast or have it completely removed? Nowadays many women can have surgery that allows them to keep the breast (breast-conserving surgery). But sometimes the entire breast needs to be removed (mastectomy) to make sure that all of the tumor tissue has gone.Chemotherapy (treatment with medication) is sometimes used to shrink larger tumors before surgery and make it easier to operate on them. This kind of treatment is called “neoadjuvant chemotherapy.”Chemotherapy is sometimes used after surgery too. Women who have a hormone-sensitive tumor may have anti-hormonal therapy. This aims to slow down tumor growth.After breast-conserving surgery the surrounding tissue is exposed to radiation, if possible, so that any remaining tumor cells can be destroyed. This is sometimes necessary after a mastectomy as well. Radiotherapy is also commonly used if the tumor cannot be surgically removed.The different types of treatment can be very difficult to go through and sometimes have very severe side effects or cause other medical problems. The side effects vary depending on the kind of treatment, but they are often easy to treat. The treatment of side effects is part of what is known as supportive care.Before deciding on whether to have a particular treatment, there is usually enough time to get information from your doctor about the possible benefits and the expected side effects, and to talk with your family or other people who are close to you. You have the right to seek a second opinion from another doctor or to decide not to have a treatment.

FDA approved drugs:

(show all 31)
# Drug Name Active Ingredient(s) 18 Company Approval Date
1
Abraxane 18 49 PACLITAXEL Celgene October 2012
2
Afinitor 18 49 EVEROLIMUS Novartis March 2009
3
Aredia 18 49 PAMIDRONATE DISODIUM Chiron August 1996
4
Arimidex 18 49 ANASTROZOLE AstraZeneca January 1996
5
Aromasin Tablets 18 49 EXEMESTANE Pharmacia & Upjohn October 21. 1999
6
CEA-Scan 18 Immunomedics April 1996
7
Ellence 18 49 EPIRUBICIN HYDROCHLORIDE Pharmacia & Upjohn September 1999
8
Evista 18 49 RALOXIFENE HYDROCHLORIDE Eli Lilly September 2007
9
Faslodex 18 49 FULVESTRANT AstraZeneca April 2002
10
Femara 18 49 LETROZOLE Novartis January 2001
11
Halaven 18 49 ERIBULIN MESYLATE Eisai November 2010
12
Herceptin 18 49 TRASTUZUMAB Genentech October 1998
13
Ibrance 18 49 PALBOCICLIB Pfizer February 2015
14
Inform HER-2/neu breast cancer test 18 Oncor January 1998
15
Iressa 18 49 GEFITINIB AstraZeneca May 2003
16
Ixempra 18 49 IXABEPILONE Bristol-Myers Squibb October 2007
17
Kadcyla 18 49 ADO-TRASTUZUMAB EMTANSINE Genentech February 2013
18
Miraluma Test 18 TECHNETIUM TC-99M SESTAMIBI KIT DuPont Merck Pharmaceutical Company May 1997
19
Neulasta 18 PEGFILGRASTIM Amgen January 2002
20
Neutroval 18 tbo-filgrastim Teva Pharmaceutical August 2012
21
Nolvadex 18 49 TAMOXIFEN CITRATE AstraZeneca October 1998
22
Perjeta 18 49 PERTUZUMAB Genentech June 2012
23
Premarin 18 ESTROGENS CONJUGATED Wyeth July of 2003
24
Self-examination breast pad 18 Inventive Products on December 22, 1995
25
Taxol 18 49 PACLITAXEL Bristol-Myers Squibb August 1997
26
Taxotere 18 49 DOCETAXEL Rhone Poulenc Rorer May 1996
27
Tykerb 18 49 LAPATINIB DITOSYLATE GlaxoSmithKline March 2007
28
Xeloda 18 49 CAPECITABINE Roche April 1998/ May 2001
29
Xgeva 18 49 DENOSUMAB Amgen June 2013/ November 2010
30
Zoladex 18 49 GOSERELIN ACETATE AstraZeneca January 1996
31
Zometa 18 49 ZOLEDRONIC ACID Novartis August 2001/ February 2002

Drugs for Breast Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1129)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Paclitaxel Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 33069-62-4 36314
2
Zoledronic acid Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 118072-93-8 68740
3
Letrozole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 112809-51-5 3902
4
Toremifene Approved, Investigational Phase 4,Phase 3,Phase 2 89778-26-7 3005573
5
Diazepam Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 2,Phase 1,Not Applicable 439-14-5 3016
6
Carboplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 41575-94-4 10339178 498142 38904
7
Epirubicin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 56420-45-2 41867
8
Lenograstim Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 135968-09-1
9
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 50-18-0, 6055-19-2 2907
10
Fluorouracil Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 51-21-8 3385
11
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 23214-92-8 31703
12
Anastrozole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 120511-73-1 2187
13
Chlorhexidine Approved, Vet_approved Phase 4,Phase 2,Not Applicable 55-56-1 9552079 2713
14
Ethanol Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 64-17-5 702
15
Iodine Approved, Investigational Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1 7553-56-2 807
16
Povidone Approved Phase 4,Phase 2 9003-39-8
17
Povidone-iodine Approved Phase 4,Phase 3 25655-41-8
18
Iron Approved Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 7439-89-6 23925
19
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2 83-43-2 6741
20
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2 50-24-8 5755
21
Triamcinolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 124-94-7 31307
22
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-28-2 5757
23 Estradiol valerate Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 979-32-8
24
Medroxyprogesterone acetate Approved, Investigational Phase 4,Phase 3,Phase 2 71-58-9
25
Polyestradiol phosphate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 28014-46-2
26
Progesterone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 57-83-0 5994
27
Ketamine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 6740-88-1 3821
28
Acetylcholine Approved Phase 4,Phase 3,Phase 2,Not Applicable 51-84-3 187
29
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-02-2 5743
30
Docetaxel Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 114977-28-5 148124
31
Ondansetron Approved Phase 4,Phase 3,Phase 2,Not Applicable 99614-02-5 4595
32
Everolimus Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 159351-69-6 6442177
33
Exemestane Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 107868-30-4 60198
34
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 22916-47-8 4189
35
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 53123-88-9 5284616 6436030 46835353
36
Tamoxifen Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 10540-29-1 2733526
37
Capecitabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 154361-50-9 60953
38
Trastuzumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 180288-69-1 9903
39
Bevacizumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 216974-75-3
40
Vinblastine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 865-21-4 13342 241903
41
Vinorelbine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 71486-22-1 60780 44424639
42
Nitrous oxide Approved, Vet_approved Phase 4,Phase 3,Not Applicable 10024-97-2 948
43
Ropivacaine Approved Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 84057-95-4 71273 175805
44
Propofol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 2078-54-8 4943
45
Sevoflurane Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 28523-86-6 5206
46
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1994-09-7, 94-09-7 2337
47
Fulvestrant Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 129453-61-8 104741 17756771
48
Lidocaine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 137-58-6 3676
49
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 15663-27-1 84093 441203 2767
50
Pregabalin Approved, Illicit, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 148553-50-8 5486971

Interventional clinical trials:

(show top 50) (show all 8806)
# Name Status NCT ID Phase Drugs
1 Benefits of Breast MRI for Predicting of Histopathologic Cell Type of Small Breast Cancer Unknown status NCT01597999 Phase 4
2 Proton MR Spectroscopy and 18F-Fluorocholine PET for Breast Cancer Diagnosis Unknown status NCT01956409 Phase 4 18F-FCH;Magnevist
3 A Clinical Trial of Paclitaxel Loaded Polymeric Micelle in Patients With Taxane-Pretreated Recurrent Breast Cancer Unknown status NCT00912639 Phase 4 Paclitaxel loaded Polymeric micelle
4 Evaluate the Relationship of Bone Remodeling Markers for Skeletal Complications in Metastatic Breast Cancer Patients Unknown status NCT00912938 Phase 4 zoledronic acid
5 Extended Adjuvant Treatment With Letrozole in Breast Cancer Who Complete 5 Years of Toremifene Unknown status NCT01072318 Phase 4 Letrozole
6 Omega-3 Fatty Acids and Chemotherapy-induced Neuropathy and Inflammation in Breast Cancer Unknown status NCT01049295 Phase 4
7 Study the Role of Positron Emission Mammography in Pre-surgical Planning for Breast Cancer Unknown status NCT00484614 Phase 4
8 Yunzhi as Dietary Supplement in Breast Cancer Unknown status NCT00647075 Phase 4
9 Paclitaxel in Combination With Carboplatin Versus Paclitaxel Plus Epirubicin in Metastatic Breast Cancer Unknown status NCT02207361 Phase 4 Paclitaxel, Carboplatin;Paclitaxel, Epirubicin
10 Filgrastim or Pegfilgrastim in Preventing Neutropenia in Women Receiving Chemotherapy Following Surgery for Breast Cancer Unknown status NCT00030758 Phase 4
11 Evaluation of Predictive Factors Regarding the Effectivity of Aromatase Inhibitor Therapy (PreFace) Unknown status NCT01908556 Phase 4 Letrozole
12 Neoadjuvant ECS Versus ECF in Local Advanced Breast Cancer Unknown status NCT01849380 Phase 4 S-1;5-FU
13 Study of the Effect of Glutamine Supplementation on Chemotherapy Induced Toxicities in Breast Cancer Patients Unknown status NCT00772824 Phase 4
14 A Study of Liposomal Doxorubicin in Women With Breast Cancer Exploiting Tissue Doppler Imaging Unknown status NCT00531973 Phase 4 liposomal doxorubicin;epirubicin
15 STARS Breast Trial (Study of Anastrozole and Radiotherapy Sequencing Pilot) Unknown status NCT00126360 Phase 4 Timing of Anastrozole in respect to radiotherapy
16 Wound Infections in Breast Cancer Surgery After Preoperative Skin Preparation With Chlorhexidine vs. Povidone-iodine Unknown status NCT02479347 Phase 4 Chlorhexidine;Povidone-Iodine
17 Weekly and Every 3 Week Administration of Paclitaxel Liposome Injection in Metastatic Breast Cancer Unknown status NCT02142790 Phase 4 paclitaxel liposome injection
18 National Screening in Denmark With MR Versus Mammography and Ultrasound of Women With BRCA1 or BRCA2 Mutations Unknown status NCT00413491 Phase 4
19 The MONET - Study: MR Mammography of Nonpalpable Breast Tumors Unknown status NCT00302120 Phase 4
20 Contrast The Role of Avitene And OK-432 in Reducing Seroma Formation After Axillary Lymphadenectomy for Breast Cancer Unknown status NCT02158299 Phase 4 Avitene;Sapylin
21 Clinical Trial Comparing Outcomes of Breast Conserving Operations With Classic v High-frequency Electrocoagulation Unknown status NCT01216254 Phase 4
22 18F-FLT Positron Emission Tomography and Magnetic Resonance Imaging of the Breast Unknown status NCT01956890 Phase 4 PET
23 Sienna+® Injection Time Study 4 Arms Unknown status NCT02612870 Phase 4
24 Does a Single Steroid Injection Reduce the Formation of Postmastectomy Seroma Unknown status NCT00307606 Phase 4 Solu-medrol 125 mg
25 Prevention of Neutropenia After Using G-CSF With TAC Chemotherapy Unknown status NCT01571518 Phase 4 late leukostim;early leukostim
26 Multi-centre Clinical Trial on Hormone Replacement Treatment in China Unknown status NCT01698164 Phase 4 estradiol plus MPA;Ximingting Tablet;estradiol plus progesterone
27 Effect of Ketalar to Prevent Postoperative Chronic Pain After Mastectomy Unknown status NCT00129597 Phase 4 ketalar
28 WHAT (Women, Hot-flashes, Activity, Trial) - Physical Activity for Treatment of Hot Flushes Among Postmenopausal Women Unknown status NCT01282320 Phase 4
29 Intraoperative Ketamine on Chronic Pain After Mastectomy Unknown status NCT02729805 Phase 4 Saline;Ketamine 0.5mg/kg;Ketamine 0.75mg/kg
30 The Use of Botulinum Toxin A in Two-Stage Tissue Expander/ Implant Breast Reconstruction Unknown status NCT01427400 Phase 4 Botulinum Toxin-A;Saline
31 Incidence of Chemotherapy-Induced Nausea and Vomiting (CINV) Associated With the Docetaxel-Cyclophosphamide Regimen in Early Breast Cancer Patients Completed NCT01298193 Phase 4 Aprepitant
32 An Open Label Study of Postmenopausal Women With Oestrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Treated With Everolimus (RAD001) With Exemestane, With Exploratory Epigenetic Marker Analysis Completed NCT01743560 Phase 4 RAD001;Exemestane
33 Randomized Trial of Follow-up Strategies in Breast Cancer Completed NCT00156039 Phase 4
34 The ODYSSEY TRIAL Phase IV Trial Evaluating the Palliative Benefit of Pamidronate or Zoledronic Acid in Breast Cancer Completed NCT01907880 Phase 4 Pamidronate;Zoledronic acid;placebo
35 Pamidronate Administration in Breast Cancer Patients With Bone Metastases Completed NCT00128297 Phase 4 Pamidronate
36 Open Label Study of Postmenopausal Women With ER and /or PgR Positive Breast Cancer Treated With Letrozole Completed NCT00237224 Phase 4 Letrozole
37 Pharmacology of Adjuvant Hormonotherapy in Breast Cancer Completed NCT01127295 Phase 4 Tamoxifen, Letrozole, Anastrozole or Exemestane
38 XeNA Study - A Study of Xeloda (Capecitabine) in Patients With Invasive Breast Cancer Completed NCT00127933 Phase 4 capecitabine [Xeloda];Taxotere;Herceptin (HER2-neu positive patients only);capecitabine [Xeloda];Taxotere
39 Life Quality and Mental State in Patients With Breast Cancer Completed NCT01458457 Phase 4
40 Maintenance Treatment With Liposomal Doxorubicin (Caelyx) in Metastatic Breast Cancer Patients Completed NCT00128778 Phase 4 Pegylated liposomal doxorubicin (Caelyx)
41 Will Preoperative MRI Breast in Women Under 56 Years With Breast Cancer Change Primary Treatment Completed NCT01859936 Phase 4
42 Circulating miRNAs as Biomarkers of Hormone Sensitivity in Breast Cancer Completed NCT01612871 Phase 4 Tamoxifen, Letrozole , Anastrozole, Exemestane
43 Comparative Efficiency of Three Regimen, CEFci, CEF and EC as Neoadjuvant Chemotherapy for Primary Breast Cancer Completed NCT01199432 Phase 4 5-FU(intravenous infusion)+epirubicin+cyclophosphamide;5-FU(intravenous bolus)+epirubicin+cyclophosphamide;epirubicin+cyclophosphamide
44 Feasibility Study for the Determination of Oxysterols in Patients With Breast Cancer Receiving Hormonal Therapy With Tamoxifen or Not Completed NCT01553903 Phase 4 Tamoxifen,;Exemestane;Anastrozole;Letrozole
45 Wellbutrin XL, Major Depressive Disorder and Breast Cancer Completed NCT00234195 Phase 4 bupropion extended release (Wellbutrin XL)
46 Eribulin Mesylate Phase IV Clinical Trial in Korean Patients With Metastatic or Locally Advanced Breast Cancer Completed NCT01961544 Phase 4 Eribulin mesylate
47 Letrozole in Treating Postmenopausal Women With Metastatic Breast Cancer Completed NCT00014638 Phase 4 letrozole
48 Arthralgia During Anastrozole Therapy for Breast Cancer Completed NCT00323479 Phase 4 Anastrozole
49 A Study of Herceptin (Trastuzumab) in Combination With a Taxane in Participants With HER2-Positive Breast Cancer Who Relapsed After (Neo)Adjuvant Herceptin Treatment Completed NCT01301729 Phase 4 Docetaxel;Paclitaxel;Trastuzumab
50 A Prospective,Open-label Study of Anastrozole in Post-menopausal Women With Hormone Sensitive Advanced Breast Cancer Completed NCT00544986 Phase 4